CDXI Stock Overview
A biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Cardax, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -99.99% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CDXI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 1.6% |
| 1Y | n/a | 14.2% | 32.3% |
Return vs Industry: Insufficient data to determine how CDXI performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CDXI performed against the US Market.
Price Volatility
| CDXI volatility | |
|---|---|
| CDXI Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CDXI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CDXI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | David Watumull | www.cardaxpharma.com |
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels.
Cardax, Inc. Fundamentals Summary
| CDXI fundamental statistics | |
|---|---|
| Market cap | US$82.00 |
| Earnings (TTM) | -US$5.43m |
| Revenue (TTM) | US$500.71k |
0.0x
P/S Ratio0.0x
P/E RatioIs CDXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDXI income statement (TTM) | |
|---|---|
| Revenue | US$500.71k |
| Cost of Revenue | US$171.51k |
| Gross Profit | US$329.19k |
| Other Expenses | US$5.76m |
| Earnings | -US$5.43m |
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CDXI perform over the long term?
See historical performance and comparison